The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Abstract
Summary: B‐cell maturation antigen (BCMA, also termed TNFRSF 17) is an attractive therapeutic target due to its restricted expression on normal and malignant plasma cells (PC). GSK 2857916 (or J6M0‐MMAF) is a BCMA‐specific antibody conjugated to the microtubule‐disrupting agent monomethyl auristatin F (MMAF) via a protease‐resistant linker. To evaluate the clinical potential of this agent, tumour cells from seventy multiple myeloma (MM) patients were assessed for BCMA expression by immunohistochemistry and flow cytometry. All patients tested expressed BCMA, at varying levels, and both surface and intracellular expression were observed. BCMA expression is maintained through relapse, extramedullary spread and in residual disease post therapy. BCMA levels may also be prognostically useful as higher levels of BCMA were associated with poorer outcomes, even taking into account genetic risk. We observed rapid internalization of surface BCMA and newly expressed protein by 1 h, suggesting a mechanism for J6M0‐MMAF activity even with low surface antigen. J6M0‐MMAF mediated cytotoxicity of MM cells varied with dose and antigen levels, with clonogenic progenitors killed at lower doses than mature cells. In comparison, J6M0‐MMAF killing of primary CD 138+ myeloma cells occurred with slower kinetics. Our observations support BCMA to be a promising therapeutic target in MM for novel therapies such as J6M0‐MMAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Cited by
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
“The levels of sBCMA have prognostic value, as patients with higher levels, particularly those ~25–325 ng/mL or higher, have poorer clinical outcomes than those with lower sBCMA values [7, 25, 29].”
BackgroundThompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 426
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Van Oekelen, O., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S., Teruya-Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01564-7 · Cited by 279
CAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270
Zah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Frerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2299 · Cited by 94
Panowski, S. H., Kuo, T. C., Zhang, Y., Chen, A., Geng, T., Aschenbrenner, L., Kamperschroer, C., Pascua, E., Chen, W., Delaria, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0007 · Cited by 48
Metadata
- Authors
- Lee, L., Bounds, D., Paterson, J., Herledan, G., Sully, K., Seestaller‐Wehr, L. M., Fieles, W. E., Tunstead, J., McCahon, L., Germaschewski, F. M., Mayes, P. A., Craigen, J. L., Rodriguez‐Justo, M., & Yong, K. L.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2016-06-17
- Volume
- 174
- Issue
- 6
- Pages
- 911-922
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2422962677
- Cited by
- 191
- References
- 2
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.